⚕ GalenOps field
←

SITE013-0372

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2023-05-13

AEs
8
Serious
1
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-05-29 (study day 7); relationship: N

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-21 (study day 122); relationship: N

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-01-11 (study day 234); relationship: N

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-07-03 (study day 408); relationship: N

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-08-14 (study day 450); relationship: not assessed

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-08-19 (study day 455); relationship: not assessed

severe assessed

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-09-12 (study day 479); relationship: N

severe serious reported

Grade 4 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-12-07 (study day 565); relationship: N; serious criteria: life-threatening

Data queries

No data queries.